Exelixis cancer drug FDA review delayed 3 months
FDA classifies Exelixis’ added zanzalintinib data as a major amendment and pushes the PDUFA action date to March 3, 2027.
Rhea-AI Filing Summary
Exelixis, Inc. (EXEL) reports that the U.S. Food and Drug Administration has extended by three months the review period for its new drug application for zanzalintinib, in combination with atezolizumab, for patients with metastatic colorectal cancer. The updated Prescription Drug User Fee Act action date is March 3, 2027.
The FDA deemed updated safety and efficacy data submitted by Exelixis to be a major amendment, which triggered the extension of the review timeline.
Positive
- None.
Negative
- Regulatory review delay: The FDA extended review of Exelixis’ zanzalintinib NDA for metastatic colorectal cancer by three months, moving the PDUFA action date to March 3, 2027, which delays any potential approval and related revenue timing.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Review extension length: 3 months
Updated PDUFA action date: March 3, 2027
Disclosure date of FDA notice: September 10, 2026
3 metrics
Review extension length
3 months
Extension of FDA review period for the zanzalintinib NDA
Updated PDUFA action date
March 3, 2027
New FDA action date for zanzalintinib NDA
Disclosure date of FDA notice
September 10, 2026
Date FDA notified Exelixis of the review extension
Key Terms
new drug application, Prescription Drug User Fee Act, major amendment, metastatic colorectal cancer, +1 more
5 terms
new drug application regulatory
"the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis’ new drug application"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
Prescription Drug User Fee Act regulatory
"The updated Prescription Drug User Fee Act action date is March 3, 2027."
A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.
major amendment regulatory
"which the FDA has deemed a major amendment."
A major amendment is a significant change to an official company document, regulatory filing, contract, or planned offering that alters key terms, disclosures, financial commitments, or investor rights. Investors care because such changes can materially affect a company’s risk, valuation, or expected returns—like revising the rules of a game mid-play, requiring reassessment of whether the investment still fits their goals.
metastatic colorectal cancer medical
"for the treatment of patients with metastatic colorectal cancer"
Metastatic colorectal cancer is cancer that started in the colon or rectum and has spread to other parts of the body, most often the liver or lungs, making it harder to treat. For investors, it matters because advanced disease drives demand for more intensive treatments, ongoing clinical trials, and long-term care costs; think of it like a fire that has jumped from one room to multiple rooms, requiring bigger, more expensive responses and creating larger market opportunities and regulatory scrutiny.
atezolizumab medical
"zanzalintinib, in combination with atezolizumab, for the treatment"
Atezolizumab is a cancer immunotherapy drug that helps the body’s immune system recognize and attack tumors by blocking a protein tumors use to hide from immune cells. For investors, it matters because approval status, clinical trial results, pricing, patent life and competition directly affect a drugmaker’s potential sales, future earnings and stock value—think of it as a new product whose market success depends on safety, effectiveness and reimbursement.
FAQ
What did the FDA decide regarding EXEL’s zanzalintinib application?
The FDA extended the review period for Exelixis’ new drug application for zanzalintinib plus atezolizumab in metastatic colorectal cancer by three months and set a new PDUFA action date of March 3, 2027.
Why was Exelixis’ (EXEL) zanzalintinib review extended?
Exelixis submitted updated safety and efficacy data in response to an FDA information request. The FDA classified this as a major amendment, which under its procedures warranted a three-month extension of the review period.
What is the new PDUFA action date for EXEL’s zanzalintinib NDA?
The updated Prescription Drug User Fee Act action date for Exelixis’ zanzalintinib NDA is March 3, 2027, following a three-month extension of the FDA review period.
Which indication is Exelixis (EXEL) seeking for zanzalintinib?
Exelixis is seeking approval of zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer, according to the disclosed NDA under FDA review.
Did Exelixis mention any issues with the zanzalintinib data in this 8-K?
The company stated it submitted updated safety and efficacy data at the FDA’s request, which the FDA deemed a major amendment. The disclosure does not describe specific issues, only that this update extended the review timeline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | |||||
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 10, 2026
 | ||
| (Exact name of registrant as specified in its charter) | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices) (Zip Code)
(650 ) 837-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
Today, Exelixis, Inc. (Exelixis) announced that on September 10, 2026, the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis’ new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer by three months. In response to an FDA information request, Exelixis had submitted updated safety and efficacy data, which the FDA has deemed a major amendment. The updated Prescription Drug User Fee Act action date is March 3, 2027.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXELIXIS, INC. | |||||||||||
| September 11, 2026 | /s/ Brenda J. Hefti | ||||||||||
| Date | Brenda J. Hefti | ||||||||||
| Senior Vice President and General Counsel | |||||||||||